Bankruptcy is far from a certainty. That is pure speculation. There are numerous irons in the fire and no ones knows what may in store in the coming weeks or months. Funding has not been an issue in the past for NP and I don’t see it being a problem at this point especially with the long haulers phase two results and what we may find out about the cancer trials.
Keep casting doubt. The company is in great position it will soon not be held back by MM and shorts. Patience will pay off for longs.
Here's what Patterson said about CytoDyn's financial future. BB posted, "Replying to @YoDoctorYo @Truthorfiction3 and 12 others Small non-revenue biopharmas survive through share dilution. So it will be for Cytodyn whomever runs it. No bankruptcy or liquidation. But less than 100 million shares added is better than less than 100 million then another 100 million to buy IncellDX."
To which Patterson replied, "And partnerships! Look at the $1.3B deal that Tango did" So Bruce is apparently optimistic that CytDyn can pull through, perhaps by entering into a partnership. If Patterson et al. can demonstrate efficacy for leronlimab in treating longhaulers, there might be a partnership down the road so that CYDY can continue to develop LL for this indication.
News 
Market Data 
Discover 
